FDA Inspection 1191835 — Scinopharm Taiwan, Ltd.

Scinopharm Taiwan, Ltd. — FEI 3002840477

The FDA completed an inspection of Scinopharm Taiwan, Ltd. on October 25, 2022 in Tainan City. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
October 25, 2022
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Tainan City (Taiwan)